Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge?
John Niederhuber named NCI chief operating officer; the surgeon was asked to leave two previous positions.
Cancer death rate dropping 1.1 percent a year, annual report finds.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40% - California’s Prop 38 is an historic approach to funding medical research, immunology
The $8.4B bond makes a long-term investment in a field with life-saving power - Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on - Facing stage 4 cholangiocarcinoma, Keaton Herzer moved mountains to take off-label therapy, get a transplant
Two years later, he has no evidence of disease - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma
